Original Article
  

Effects of CB2 Receptor Inverse Agonist on Airway Remodeling and Th1/Th2 Imbalance in Bronchial Asthma Rats via TLR4/NF-κB Signaling Pathway

Abstract

Bronchial asthma (BA) has a complex pathogenesis involving immune imbalance and airway remodeling (AR). Cannabinoid receptor 2 (CB2) plays a role in inflammation regulation, so this study explored the therapeutic potential of a CB2 inverse agonist on BA rats’ AR and Th1/Th2 imbalance, and its mechanism via Toll-like receptor 4/nuclear factor kappa B(TLR4/NF-κB) pathway.
Twenty-seven male SD rats (180-220 g) were divided into control (CG), model (MG), and intervention (IG) groups (n=9 each). MG/IG were BA-modeled by ovalbumin (OVA) sensitization (days 1/8: 100 μg OVA +1 mg aluminum hydroxide gel, i.p.) and 1% OVA aerosol challenge (day 15, 3×/week, 8 weeks). IG received CB2 inverse agonist (5 mg/kg, i.p., 3×/week, 4 weeks); CG/MG got saline. TH1/TH2 cytokines, subsets, AR parameters, and lung TLR4/NF-κB-related molecules were detected.
Compared with CG, MG had TH1/TH2 imbalance, higher AR indices, upregulated TLR4/NF-κB, shorter asthma latency, and longer attack duration. vs. MG, IG reversed TH1/TH2 imbalance, reduced TLR4/NF-κB-related protein/mRNA (except elevated NFKBIA).
CB2 inverse agonist has BA prevention/treatment potential by regulating Th1/Th2 balance, inhibiting AR, and acting on the TLR4/NF-κB pathway.

1. Qian K, Xu H, Chen Z, Zheng Y. Advances in pulmonary rehabilitation for children with bronchial asthma. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2023;52(4):518–25.
2. Chetta A, Calzetta L. Bronchial asthma: an update. Minerva Med. 2022;113(1):1–3.
3. Savin IA, Zenkova MA, Sen’kova AV. Bronchial asthma, airway remodeling, and lung fibrosis as successive steps of one process. Int J Mol Sci. 2023;24(22):16042.
4. Kama Y, Yamada Y, Koike T, Suzuki K, Enseki M, Hirai K, et al. Antibiotic treatments prolong the wheezing period in acute exacerbation of childhood bronchial asthma. Int Arch Allergy Immunol. 2022;183(6):617–27.
5. Liu H, Tang T. MAPK signaling pathway-based glioma subtypes, machine-learning risk model, and key hub proteins identification. Sci Rep. 2023;13(1):19055.
6. Britt RD Jr, Ruwanpathirana A, Ford ML, Lewis BW. Macrophages orchestrate airway inflammation, remodeling, and resolution in asthma. Int J Mol Sci. 2023;24(13):10451.
7. Liu H, Li Y. Potential roles of cornichon family AMPA receptor auxiliary protein 4 (CNIH4) in head and neck squamous cell carcinoma. Cancer Biomark. 2022;35(4):439–50.
8. Garagorri-Gutiérrez D, Leirós-Rodríguez R. Effects of physiotherapy treatment in patients with bronchial asthma: A systematic review. Physiother Theory Pract. 2022;38(4):493–503.
9. Thomas D, McDonald VM, Pavord ID, Gibson PG. Asthma remission: what is it and how can it be achieved? Eur Respir J. 2022;60(5):2102583.
10. Chung KF, Dixey P, Abubakar-Waziri H, Bhavsar P, Patel PH, Guo S, et al. Characteristics, phenotypes, mechanisms, and management of severe asthma. Chin Med J (Engl). 2022;135(10):1141–55.
11. Fong KY, Zhao JJ, Syn NL, Nair P, Chan YH, Lee P. Comparing bronchial thermoplasty with biologicals for severe asthma: Systematic review and network meta-analysis. Respir Med. 2023;216:107302.
12. Matucci A, Micheletto C, Vultaggio A. Severe asthma and biologics: managing complex patients. J InvestigAllergol Clin Immunol. 2023;33(3):168–78.
13. Rajvanshi N, Kumar P, Goyal JP. Global initiative for asthma guidelines 2024: an update. Indian Pediatr. 2024;61(8):781–6.
14. Dhangar S, Shanmukhaiah C, Sawant L, Ghatanatti J, Shah A, Mathan SLP, et al. Synergetic effect of azacitidine and sorafenib in treatment of a case of myeloid neoplasm with sole chromosomal abnormality t(8;22)(p11.2;q11.2)/BCR-FGFR1 rearrangement. Cancer Genet. 2023;274–5:26–9.
15. Barosova R, Baranovicova E, Hanusrichterova J, Mokra D. Metabolomics in animal models of bronchial asthma and its translational importance for clinics. Int J Mol Sci. 2023;25(1):459.
16. Li C, Xin H, Yun L, BoWen L, KunLu S, JiangTao L. Bronchial thermoplasty for severe asthma: potential mechanisms and response markers. Ther Adv Respir Dis. 2024;18:17534666241266348.
17. Leung C, Sin DD. Asthma-COPD overlap: what are the important questions? Chest. 2022;161(2):330–44.
18. Dai Y, Jin N. Association and interacting factors between bronchial asthma and attention-deficit hyperactivity disorder in children: meta-analysis and systematic review. Actas Esp Psiquiatr. 2023;51(6):262–70.
19. Habib N, Pasha MA, Tang DD. Current understanding of asthma pathogenesis and biomarkers. Cells. 2022;11(17):2764.
20. Amison RT, Page CP. Novel pharmacological therapies for the treatment of bronchial asthma. Minerva Med. 2022;113(1):31–50.
21. Ano S, Kikuchi N, Matsuyama M, Hizawa N. Patient profiling to predict response to bronchial thermoplasty in patients with severe asthma. Respir Investig. 2023;61(6):675–81.
22. Nakagome K, Nagata M. The possible roles of IL-4/IL-13 in the development of eosinophil-predominant severe asthma. Biomolecules. 2024;14(5):546.
Files
IssueArticles in Press QRcode
SectionOriginal Article(s)
Keywords
Airway remodeling Bronchial asthma CB2 receptor inverse agonist Immune imbalance TLR4/NF-κB pathway
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Zhou W, Gao J. Effects of CB2 Receptor Inverse Agonist on Airway Remodeling and Th1/Th2 Imbalance in Bronchial Asthma Rats via TLR4/NF-κB Signaling Pathway. Iran J Allergy Asthma Immunol. 2026;:1-13.